TiGenix was acquired by Takeda Pharmaceutical for approximately $622.5 million. Takeda anticipates approval from the European Medicines Agency for TiGenix's Crohn's disease cell therapy Alofisel, or darvadstrocel, this year.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.